Ajanta Pharma retains the tag of fastest wealth creator for the third time in a row and Asian Paints is the most consistent wealth creator, said the wealth creation study
Natco Pharma said it plans to utilize the cash flows generated by the launch of generic versions of Israel-based Teva’s top selling multiple sclerosis Copaxone 20 mg/ml and 40 mg/ml by its partner Mylan in US towards strengthening balance sheet and investing on business expansion.
In an interview to CNBC-TV18, Anmol Ganjoo, Director of JM Financial Institutional Securities spoke about his latest report on Indian pharmaceutical space. Ganjoo has written on multiple stocks as well as the entire framework of the pharmaceutical space.
In the latest, CNBC-TV18's Ekta Batra and Vikas Dandekar caught up with Saumen Chakraborty, CFO of Dr Reddy's Laboratories (DRL) and asked him amongst other things, if pharmaceutical companies like DRL will feel the jitters once GST is rolled out.
Shereen Bhan speaks with top bosses from the pharma sector along with KT Rama Rao, Minister of IT, Telangana at Bioasia 2017 to discuss way forward for pharma sector in making India healthier.
Saumen Chakraborty, CFO of Dr Reddy's is confident of getting back on to the growth path starting FY18 on the back of more than 15 significant launches and approvals that will help the pharma major make a comeback.
Wockhardt chief Habil Khorakiwala says that Indian generic company as a whole is a competitive industry in US and therefore there is no scope for government intervention there. Anmol Ganjoo of JM Financial says if drug prices come down then Indian pharma companies will benefit.
Of the total 18 observations, 9 from July 2015 and another 9 from March 2016 inspection, the former ones relating to equipment and warehousing have been closed. Nine observations are still outstanding for the company.
Saumen Chakraborty, CFO of the company told CNBC-TV18 that they hope to commercialise four out of the eight products by FY18. He said all the eight products are expected to have limited competition.
Pharma companies are losing market share and such deals help them,says Surajit Pal of Prabhudas Lilladher.
Executives of Dr Reddy's Laboratories and Citi tell CNBC-TV18 that the second half of 2016 should be a good one for pharma industry.
Company will continue with tie-ups for biosimilar products. These will first be launched in India and then in other markets, says Satish Reddy, Chairman of Dr Reddy‘s Lab.
In the last five months, plants of nine Indian pharmaceutical companies - Cipla, Dr Reddy‘s, Sun Pharma, Cadila, Lupin and Natco Pharma.- have come under the US Food and Drug Administration (FDA) scanner.
When asked about the Cipla Indore facility, which has come under the USFDA scanner for manufacturing norms violations, Talati reassures that the facility is not a major contributer to Cipla earnings. Hence this news, he feels should not affect sales.
Saumen Chakraborty, President and CFO, Dr Reddy's Lab said they will be making a proposal to the board for buying back equity shares on February 17.
Sharma, however, believes that despite the issues getting compounded by the day, most of the companies have enough capabilities to resolve them within the next 12-15 months.
In an interview with CNBC-TV18, Surya Patra, Vice President Pharma - Institutional Equity Research at Phillipcapital, says that the company has cut its FY17 estimates for Sun Pharma by 5 percent.
Saumen Chakraborty, CFO, Dr Reddy's Laboratories, says "The warning letter has come telling the management to respond within 15 working days in terms of strategy and plan."
Surya Narayan Patra of Phillipcapital says the news on Elepsia is more relevant to Sun Pharma. The product was linked to one of the facilities linked to USFDA issues
Speaking on acquisitions, Satish Reddy, Chairman of Dr Reddy's said they are always on the lookout for strategic fits to boost growth.
According to Alok Sonig of DRL, the acquired brands have grown historically at lower double-digits and have a lot of headroom to grow further
The company has 20 facilities across the globe with portfolio of more than 200 products in 138 countries.
GV Prasad, Co-Chairman & CEO of Dr Reddy‘s Laboratories said a lot of growth is seen in emerging markets
As 2014 comes to an end, Surajit Pal of Prabhudas Lilladher shares his outlook on the year that was and the possible trends for 2015.
Ranbaxy has first-to-file status, meaning eligibility for six months of generic sales exclusivity for both AstraZeneca's heartburn drug Nexium & Roche's antiviral drug Valcyte drugs. However, the final approvals for these drugs were delayed because of the compliance issues at Ranbaxy's plants.